JPH0153244B2 - - Google Patents
Info
- Publication number
- JPH0153244B2 JPH0153244B2 JP55108390A JP10839080A JPH0153244B2 JP H0153244 B2 JPH0153244 B2 JP H0153244B2 JP 55108390 A JP55108390 A JP 55108390A JP 10839080 A JP10839080 A JP 10839080A JP H0153244 B2 JPH0153244 B2 JP H0153244B2
- Authority
- JP
- Japan
- Prior art keywords
- chloridalol
- cholesterol
- patients
- diet
- administered
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- KBFBRIPYVVGWRS-UHFFFAOYSA-N cloridarol Chemical compound C=1C2=CC=CC=C2OC=1C(O)C1=CC=C(Cl)C=C1 KBFBRIPYVVGWRS-UHFFFAOYSA-N 0.000 claims description 5
- 239000003814 drug Substances 0.000 claims description 2
- 229940124597 therapeutic agent Drugs 0.000 claims description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 24
- 235000012000 cholesterol Nutrition 0.000 description 11
- 235000005911 diet Nutrition 0.000 description 8
- 230000037213 diet Effects 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 5
- 241000700159 Rattus Species 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- KNHUKKLJHYUCFP-UHFFFAOYSA-N clofibrate Chemical compound CCOC(=O)C(C)(C)OC1=CC=C(Cl)C=C1 KNHUKKLJHYUCFP-UHFFFAOYSA-N 0.000 description 5
- 210000004185 liver Anatomy 0.000 description 5
- 229960001214 clofibrate Drugs 0.000 description 4
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 4
- 229960001261 cloridarol Drugs 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 239000004006 olive oil Substances 0.000 description 3
- 235000008390 olive oil Nutrition 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 229940125753 fibrate Drugs 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- BHQCQFFYRZLCQQ-UHFFFAOYSA-N (3alpha,5alpha,7alpha,12alpha)-3,7,12-trihydroxy-cholan-24-oic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 BHQCQFFYRZLCQQ-UHFFFAOYSA-N 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 239000004380 Cholic acid Substances 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- BHQCQFFYRZLCQQ-OELDTZBJSA-N cholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 description 1
- 229960002471 cholic acid Drugs 0.000 description 1
- 235000019416 cholic acid Nutrition 0.000 description 1
- 239000003240 coconut oil Substances 0.000 description 1
- 235000019864 coconut oil Nutrition 0.000 description 1
- KXGVEGMKQFWNSR-UHFFFAOYSA-N deoxycholic acid Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 KXGVEGMKQFWNSR-UHFFFAOYSA-N 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 230000001258 dyslipidemic effect Effects 0.000 description 1
- 201000005577 familial hyperlipidemia Diseases 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- FFEARJCKVFRZRR-UHFFFAOYSA-N methionine Chemical compound CSCCC(N)C(O)=O FFEARJCKVFRZRR-UHFFFAOYSA-N 0.000 description 1
- 235000021590 normal diet Nutrition 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000011833 salt mixture Substances 0.000 description 1
- 235000000891 standard diet Nutrition 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Hematology (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Furan Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT7909513A IT1207887B (it) | 1979-08-10 | 1979-08-10 | Uso in terapia del prodotto (2benzofuril)-(p-clorofenil)-carbino lo(cloridarol dci)come normolipide mizzante e antiaggregante piastrinico |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS5645413A JPS5645413A (en) | 1981-04-25 |
| JPH0153244B2 true JPH0153244B2 (ref) | 1989-11-13 |
Family
ID=11131363
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP10839080A Granted JPS5645413A (en) | 1979-08-10 | 1980-08-08 | Normalipidemizer and blood platelet antibinder |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US4296124A (ref) |
| JP (1) | JPS5645413A (ref) |
| BE (1) | BE884691A (ref) |
| CA (1) | CA1155395A (ref) |
| CH (1) | CH648756A5 (ref) |
| DE (1) | DE3029421A1 (ref) |
| FR (1) | FR2463135A1 (ref) |
| GB (1) | GB2056280A (ref) |
| IT (1) | IT1207887B (ref) |
| LU (1) | LU82700A1 (ref) |
| NL (1) | NL8004534A (ref) |
| ZA (1) | ZA804822B (ref) |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1160925A (en) | 1967-02-08 | 1969-08-06 | Menarini Sas | 2-Substituted Benzofuran Derivatives |
-
1979
- 1979-08-10 IT IT7909513A patent/IT1207887B/it active
-
1980
- 1980-08-01 GB GB8025197A patent/GB2056280A/en not_active Withdrawn
- 1980-08-02 DE DE19803029421 patent/DE3029421A1/de active Granted
- 1980-08-07 ZA ZA00804822A patent/ZA804822B/xx unknown
- 1980-08-08 CH CH6040/80A patent/CH648756A5/it not_active IP Right Cessation
- 1980-08-08 BE BE0/201683A patent/BE884691A/fr not_active IP Right Cessation
- 1980-08-08 LU LU82700A patent/LU82700A1/fr unknown
- 1980-08-08 NL NL8004534A patent/NL8004534A/nl not_active Application Discontinuation
- 1980-08-08 JP JP10839080A patent/JPS5645413A/ja active Granted
- 1980-08-11 US US06/176,867 patent/US4296124A/en not_active Expired - Lifetime
- 1980-08-11 CA CA000357982A patent/CA1155395A/en not_active Expired
- 1980-08-11 FR FR8017691A patent/FR2463135A1/fr active Granted
Also Published As
| Publication number | Publication date |
|---|---|
| FR2463135B1 (ref) | 1983-08-12 |
| CA1155395A (en) | 1983-10-18 |
| IT1207887B (it) | 1989-06-01 |
| NL8004534A (nl) | 1981-02-12 |
| FR2463135A1 (fr) | 1981-02-20 |
| GB2056280A (en) | 1981-03-18 |
| BE884691A (fr) | 1980-12-01 |
| DE3029421C2 (ref) | 1990-02-22 |
| DE3029421A1 (de) | 1981-02-26 |
| JPS5645413A (en) | 1981-04-25 |
| ZA804822B (en) | 1981-08-26 |
| US4296124A (en) | 1981-10-20 |
| CH648756A5 (it) | 1985-04-15 |
| LU82700A1 (fr) | 1980-12-15 |
| IT7909513A0 (it) | 1979-08-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69901396T2 (de) | Zusammensetzung enthaltend beta-hydroxy-beta-methylbutyratsäuere und mindestens ein aminosäure | |
| Lieber et al. | Ammonia as a source of gastric hypoacidity in patients with uremia | |
| DE69028712T2 (de) | Zusammensetzung zur behandlung entzündlicher darmerkrankungen | |
| Walshe | Tetrathiomolybdate (MoS4) as an ‘anti-copper’agent in man | |
| CH666188A5 (de) | Immuno-regulator in form einer pharmazeutischen zusammensetzung. | |
| JP2002502816A (ja) | 鉄キレート化療法のためのｎ，ｎ’−ビス（２−ヒドロキシベンジル）エチレンジアミン−ｎ，ｎ’−二酢酸を含む薬剤 | |
| CH680704A5 (ref) | ||
| Ansell | Management of polymyositis and dermatomyositis | |
| US2761807A (en) | Glycocyamine and methylating agent in vivo creatine producing composition | |
| JP3032315B2 (ja) | 脂肪肝治療剤 | |
| US4608258A (en) | Medicament for treatment of diarrhea | |
| Obase et al. | Efficacy and safety of long-term treatment of asthmatic patients with pranlukast, a cysteinyl-leukotriene-receptor antagonist: four-year followup study | |
| US2935448A (en) | Phosphatide therapeutic composition and method of treatment therewith | |
| DE69308762T2 (de) | Behandlung des Muskulschwunds | |
| JPH0153244B2 (ref) | ||
| CN115252626B (zh) | 一种含糖皮质激素的药物组合物及其应用 | |
| JP3253878B2 (ja) | 鉄キレート化用製剤、その製剤の製法及び地中海貧血症の治療法 | |
| EP0990441A1 (en) | A drug for treating diabetic nephrosis | |
| DE2759108A1 (de) | Verwendung von alpha -mercapto-beta- aryl-acrylsaeuren bei der steigerung des zinkgehaltes im serum und im gewebe | |
| Shearer et al. | Influence of cadmium on caries and the cariostatic properties of fluoride in rats | |
| US6197818B1 (en) | Drug for treating diabetic nephrosis | |
| EP0087744B1 (en) | Lipid metabolism improving agents | |
| DE3141970A1 (de) | Arzneimittel zur behandlung der durch den virus der herpes-gruppe erzeugten erkrankungen | |
| CN106309456B (zh) | 人参皂苷在抗磷脂体综合征分子靶向治疗药物制备中的应用 | |
| DE69016232T2 (de) | Verwendung von Dimercaptobernsteinsäure zur Behandlung von mit Silizium-Überschuss in Verbindung stehenden Störungen im Blut oder Gewebe. |